Search research articles
Contact Us
Filters
Showing results (31-40 of 72) with videos related to
Page
of 8
Sort By:
NPJ Parkinson'S Disease
|
October 21, 2022
Neuromelanin and T<sub>2</sub>*-MRI for the assessment of genetically at-risk, prodromal, and symptomatic Parkinson's disease
Dafna Ben Bashat, Avner Thaler, Hedva Lerman Shacham, et al.
Scientific Reports
|
June 11, 2020
Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson's disease
Avner Thaler, Shani Shenhar-Tsarfaty, Yanay Shaked, et al.
Investigative Ophthalmology & Visual Science
|
November 24, 2006
Dynamic and quantitative analysis of choroidal neovascularization by fluorescein angiography
Syed Mahmood Shah, Sinan Tatlipinar, Edward Quinlan, et al.
Molecular Genetics and Metabolism
|
October 31, 2019
Revisiting the non-Gaucher-GBA-E326K carrier state: Is it sufficient to increase Parkinson's disease risk?
Orly Goldstein, Mali Gana-Weisz, Danielle Cohen-Avinoam, et al.
Journal of Parkinson'S Disease
|
May 17, 2021
Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers
Avner Thaler, Nurit Omer, Nir Giladi, et al.
The American Journal of Gastroenterology
|
June 24, 2003
Neurotrophin-3 improves functional constipation
Henry P Parkman, Satish S C Rao, James C Reynolds, et al.
NPJ Parkinson'S Disease
|
March 4, 2022
Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers
Amgad Droby, Moran Artzi, Hedva Lerman, et al.
Digital Biomarkers
|
March 17, 2020
Metadata Concepts for Advancing the Use of Digital Health Technologies in Clinical Research
Reham Badawy, Farhan Hameed, Lauren Bataille, et al.
Parkinsonism & Related Disorders
|
May 1, 2024
Mild cognitive impairment among LRRK2 and GBA1 patients with Parkinson's disease
Avner Thaler, Vered Livne, Einat Rubinstein, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases
|
May 18, 2012
Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis
Jeremy Shefner, Jesse M Cedarbaum, Merit E Cudkowicz, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 72) with videos related to
Sort By:
Page
of 8
NPJ Parkinson'S Disease
|
October 21, 2022
Neuromelanin and T<sub>2</sub>*-MRI for the assessment of genetically at-risk, prodromal, and symptomatic Parkinson's disease
Dafna Ben Bashat, Avner Thaler, Hedva Lerman Shacham, et al.
Scientific Reports
|
June 11, 2020
Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson's disease
Avner Thaler, Shani Shenhar-Tsarfaty, Yanay Shaked, et al.
Investigative Ophthalmology & Visual Science
|
November 24, 2006
Dynamic and quantitative analysis of choroidal neovascularization by fluorescein angiography
Syed Mahmood Shah, Sinan Tatlipinar, Edward Quinlan, et al.
Molecular Genetics and Metabolism
|
October 31, 2019
Revisiting the non-Gaucher-GBA-E326K carrier state: Is it sufficient to increase Parkinson's disease risk?
Orly Goldstein, Mali Gana-Weisz, Danielle Cohen-Avinoam, et al.
Journal of Parkinson'S Disease
|
May 17, 2021
Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers
Avner Thaler, Nurit Omer, Nir Giladi, et al.
The American Journal of Gastroenterology
|
June 24, 2003
Neurotrophin-3 improves functional constipation
Henry P Parkman, Satish S C Rao, James C Reynolds, et al.
NPJ Parkinson'S Disease
|
March 4, 2022
Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers
Amgad Droby, Moran Artzi, Hedva Lerman, et al.
Digital Biomarkers
|
March 17, 2020
Metadata Concepts for Advancing the Use of Digital Health Technologies in Clinical Research
Reham Badawy, Farhan Hameed, Lauren Bataille, et al.
Parkinsonism & Related Disorders
|
May 1, 2024
Mild cognitive impairment among LRRK2 and GBA1 patients with Parkinson's disease
Avner Thaler, Vered Livne, Einat Rubinstein, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases
|
May 18, 2012
Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis
Jeremy Shefner, Jesse M Cedarbaum, Merit E Cudkowicz, et al.
Page
of 8